THE ASSOCIATION OF P2Y12 INHIBITOR COPAYMENT REDUCTION WITH OUTCOMES AT HOSPITALS WITH AND WITHOUT MEDICATION ASSISTANCE PROGRAMSdoi:10.1016/s0735-1097(19)30803-4Jacob Appel DollLisa KaltenbachKevin AnstromGregg FonarowChristopher CannonTimothy Henry...
This open-label randomized trial compares the effect of a genotype-guided oral P2Y12 inhibitor selection strategy vs conventional clopidogrel prescribing
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. 关联 37 项与P2Y12 receptor 相关的药物 Prasugrel Hydrochloride/Aspirin 盐酸普拉格雷/阿司匹林 靶点 COX...
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical TrialCOPAYMENTS (Insurance)PLATELET aggregation inhibitorsCARDIOVASCULAR diseases...
To define the circulating miRNA response to endotoxemia without common confounders such as medication and co-morbidities in critically-ill sepsis patients, we employed an experimental low-dose endotoxemia model in combination with P2Y12 inhibitor treatment in healthy volunteers. Findings were subsequently ...